OA12701A - Use of biologically active HIV-1 TAT, fragments orderivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccinati on and/or to treat other diseases. - Google Patents

Use of biologically active HIV-1 TAT, fragments orderivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccinati on and/or to treat other diseases. Download PDF

Info

Publication number: OA12701A
Authority: OA; OAPI
Prior art keywords: tat; aids; lys; pro; arg
Prior art date: 2001-07-26

Application number

OA1200400015A

Other languages

English (en)

Inventor

Barbara Ensoli

Original Assignee

Ist Superiore Sanita

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-26

Filing date

2002-07-26

Publication date

2006-06-23

2002-07-26 Application filed by Ist Superiore Sanita filed Critical Ist Superiore Sanita

2006-06-23 Publication of OA12701A publication Critical patent/OA12701A/en

Links

241000713772 Human immunodeficiency virus 1 Species 0.000 title claims abstract description 48
239000012634 fragment Substances 0.000 title claims abstract description 48
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 44
210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 43
201000010099 disease Diseases 0.000 title claims abstract description 41
230000001225 therapeutic effect Effects 0.000 title claims abstract description 33
230000003449 preventive effect Effects 0.000 title abstract description 4
101710149951 Protein Tat Proteins 0.000 claims abstract description 570
210000004027 cell Anatomy 0.000 claims abstract description 196
239000000427 antigen Substances 0.000 claims abstract description 106
108091007433 antigens Proteins 0.000 claims abstract description 106
102000036639 antigens Human genes 0.000 claims abstract description 106
206010028980 Neoplasm Diseases 0.000 claims abstract description 44
230000028993 immune response Effects 0.000 claims abstract description 41
238000002255 vaccination Methods 0.000 claims abstract description 32
208000035473 Communicable disease Diseases 0.000 claims abstract description 31
210000002540 macrophage Anatomy 0.000 claims abstract description 31
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 30
239000002671 adjuvant Substances 0.000 claims abstract description 26
150000001875 compounds Chemical class 0.000 claims abstract description 26
230000002757 inflammatory effect Effects 0.000 claims abstract description 25
230000002491 angiogenic effect Effects 0.000 claims abstract description 24
210000004443 dendritic cell Anatomy 0.000 claims abstract description 17
230000035800 maturation Effects 0.000 claims abstract description 17
108020004414 DNA Proteins 0.000 claims description 76
108090000623 proteins and genes Proteins 0.000 claims description 57
102000004169 proteins and genes Human genes 0.000 claims description 56
108090000765 processed proteins & peptides Proteins 0.000 claims description 54
102000006495 integrins Human genes 0.000 claims description 52
108010044426 integrins Proteins 0.000 claims description 52
102000004196 processed proteins & peptides Human genes 0.000 claims description 44
102000004127 Cytokines Human genes 0.000 claims description 39
108090000695 Cytokines Proteins 0.000 claims description 39
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 38
208000015181 infectious disease Diseases 0.000 claims description 27
230000037361 pathway Effects 0.000 claims description 25
238000004519 manufacturing process Methods 0.000 claims description 21
230000001404 mediated effect Effects 0.000 claims description 21
230000014509 gene expression Effects 0.000 claims description 19
241000700605 Viruses Species 0.000 claims description 18
230000004044 response Effects 0.000 claims description 18
210000001744 T-lymphocyte Anatomy 0.000 claims description 15
244000052769 pathogen Species 0.000 claims description 15
230000003834 intracellular effect Effects 0.000 claims description 14
238000000338 in vitro Methods 0.000 claims description 13
201000004792 malaria Diseases 0.000 claims description 11
210000000481 breast Anatomy 0.000 claims description 10
210000001072 colon Anatomy 0.000 claims description 10
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
210000004072 lung Anatomy 0.000 claims description 10
102000019034 Chemokines Human genes 0.000 claims description 9
108010012236 Chemokines Proteins 0.000 claims description 9
241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
229960005486 vaccine Drugs 0.000 claims description 9
241000222120 Candida <Saccharomycetales> Species 0.000 claims description 8
208000031886 HIV Infections Diseases 0.000 claims description 8
241000187479 Mycobacterium tuberculosis Species 0.000 claims description 8
206010060862 Prostate cancer Diseases 0.000 claims description 8
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
238000001727 in vivo Methods 0.000 claims description 8
239000002245 particle Substances 0.000 claims description 8
210000004881 tumor cell Anatomy 0.000 claims description 8
206010061218 Inflammation Diseases 0.000 claims description 7
230000004054 inflammatory process Effects 0.000 claims description 7
238000007918 intramuscular administration Methods 0.000 claims description 6
239000002502 liposome Substances 0.000 claims description 6
239000011859 microparticle Substances 0.000 claims description 6
239000002105 nanoparticle Substances 0.000 claims description 6
230000002458 infectious effect Effects 0.000 claims description 5
-1 nanoparticies Substances 0.000 claims description 5
229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
230000001580 bacterial effect Effects 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 4
210000000170 cell membrane Anatomy 0.000 claims description 4
229940043239 cytotoxic antineoplastic drug Drugs 0.000 claims description 4
239000013604 expression vector Substances 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
230000009826 neoplastic cell growth Effects 0.000 claims description 4
239000000243 solution Substances 0.000 claims description 4
230000009885 systemic effect Effects 0.000 claims description 4
241001430294 unidentified retrovirus Species 0.000 claims description 4
208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
230000000840 anti-viral effect Effects 0.000 claims description 3
210000004369 blood Anatomy 0.000 claims description 3
239000008280 blood Substances 0.000 claims description 3
208000006454 hepatitis Diseases 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 3
230000002519 immonomodulatory effect Effects 0.000 claims description 3
201000008827 tuberculosis Diseases 0.000 claims description 3
239000013598 vector Substances 0.000 claims description 3
206010065452 Angiodermatitis Diseases 0.000 claims description 2
208000028185 Angioedema Diseases 0.000 claims description 2
201000001320 Atherosclerosis Diseases 0.000 claims description 2
241000894006 Bacteria Species 0.000 claims description 2
208000010412 Glaucoma Diseases 0.000 claims description 2
208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
208000004898 Herpes Labialis Diseases 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
108010028921 Lipopeptides Proteins 0.000 claims description 2
206010067152 Oral herpes Diseases 0.000 claims description 2
206010031252 Osteomyelitis Diseases 0.000 claims description 2
241000607142 Salmonella Species 0.000 claims description 2
206010039491 Sarcoma Diseases 0.000 claims description 2
241000194017 Streptococcus Species 0.000 claims description 2
201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
206010042953 Systemic sclerosis Diseases 0.000 claims description 2
206010043376 Tetanus Diseases 0.000 claims description 2
206010047115 Vasculitis Diseases 0.000 claims description 2
241000607626 Vibrio cholerae Species 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
229940037003 alum Drugs 0.000 claims description 2
210000000988 bone and bone Anatomy 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
201000003984 candidiasis Diseases 0.000 claims description 2
210000000845 cartilage Anatomy 0.000 claims description 2
239000006071 cream Substances 0.000 claims description 2
206010014665 endocarditis Diseases 0.000 claims description 2
210000000750 endocrine system Anatomy 0.000 claims description 2
210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
206010066435 human herpesvirus 8 infection Diseases 0.000 claims description 2
201000001371 inclusion conjunctivitis Diseases 0.000 claims description 2
201000006747 infectious mononucleosis Diseases 0.000 claims description 2
210000004185 liver Anatomy 0.000 claims description 2
201000008482 osteoarthritis Diseases 0.000 claims description 2
210000001672 ovary Anatomy 0.000 claims description 2
208000003154 papilloma Diseases 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
206010036784 proctocolitis Diseases 0.000 claims description 2
201000000306 sarcoidosis Diseases 0.000 claims description 2
208000017520 skin disease Diseases 0.000 claims description 2
210000004872 soft tissue Anatomy 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
208000006379 syphilis Diseases 0.000 claims description 2
206010044325 trachoma Diseases 0.000 claims description 2
208000019206 urinary tract infection Diseases 0.000 claims description 2
230000002792 vascular Effects 0.000 claims description 2
229940118696 vibrio cholerae Drugs 0.000 claims description 2
230000009385 viral infection Effects 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
241000714195 Aids-associated retrovirus Species 0.000 claims 99
HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 claims 15
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 13
239000008194 pharmaceutical composition Substances 0.000 claims 12
108010061238 threonyl-glycine Proteins 0.000 claims 10
SRWWRLKBEJZFPW-IHRRRGAJSA-N Val-Cys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N SRWWRLKBEJZFPW-IHRRRGAJSA-N 0.000 claims 9
RVMXMLSYBTXCAV-VEVYYDQMSA-N Asp-Pro-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMXMLSYBTXCAV-VEVYYDQMSA-N 0.000 claims 8
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 8
WFIVLLFYUZZWOD-RHYQMDGZSA-N Pro-Lys-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WFIVLLFYUZZWOD-RHYQMDGZSA-N 0.000 claims 8
VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 claims 8
XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 claims 7
RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 claims 7
FFCRCJZJARTYCG-KKUMJFAQSA-N Tyr-Cys-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N)O FFCRCJZJARTYCG-KKUMJFAQSA-N 0.000 claims 7
108010054155 lysyllysine Proteins 0.000 claims 7
FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 claims 6
108010085325 histidylproline Proteins 0.000 claims 6
UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 claims 5
OETOANMAHTWESF-KKUMJFAQSA-N Cys-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CS)N OETOANMAHTWESF-KKUMJFAQSA-N 0.000 claims 5
GAAHQHNCMIAYEX-UWVGGRQHSA-N Gly-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GAAHQHNCMIAYEX-UWVGGRQHSA-N 0.000 claims 5
CLBGMWIYPYAZPR-AVGNSLFASA-N Lys-Arg-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O CLBGMWIYPYAZPR-AVGNSLFASA-N 0.000 claims 5
OWSRIUBVJOQHNY-IHPCNDPISA-N Trp-Lys-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N OWSRIUBVJOQHNY-IHPCNDPISA-N 0.000 claims 5
108010029539 arginyl-prolyl-proline Proteins 0.000 claims 5
101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 claims 4
JIVJQYNNAYFXDG-LKXGYXEUSA-N Cys-Thr-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JIVJQYNNAYFXDG-LKXGYXEUSA-N 0.000 claims 4
PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 claims 4
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims 4
VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 claims 4
WXVIGTAUZBUDPZ-DTLFHODZSA-N Thr-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 WXVIGTAUZBUDPZ-DTLFHODZSA-N 0.000 claims 4
108010062796 arginyllysine Proteins 0.000 claims 4
108010009298 lysylglutamic acid Proteins 0.000 claims 4
MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 claims 3
OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 claims 3
OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 claims 3
BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 claims 3
CZIXHXIJJZLYRJ-SRVKXCTJSA-N Asn-Cys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CZIXHXIJJZLYRJ-SRVKXCTJSA-N 0.000 claims 3
KGIHMGPYGXBYJJ-SRVKXCTJSA-N Cys-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS KGIHMGPYGXBYJJ-SRVKXCTJSA-N 0.000 claims 3
QCBYAHHNOHBXIH-UWVGGRQHSA-N His-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CN=CN1 QCBYAHHNOHBXIH-UWVGGRQHSA-N 0.000 claims 3
QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 claims 3
CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 claims 3
KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 claims 3
OGAZPKJHHZPYFK-GARJFASQSA-N Met-Glu-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGAZPKJHHZPYFK-GARJFASQSA-N 0.000 claims 3
101100084404 Mus musculus Prodh gene Proteins 0.000 claims 3
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 claims 3
GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 claims 3
DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 claims 3
FYXCBXDAMPEHIQ-FHWLQOOXSA-N Pro-Trp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)O FYXCBXDAMPEHIQ-FHWLQOOXSA-N 0.000 claims 3
DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 claims 3
108010068380 arginylarginine Proteins 0.000 claims 3
108010050848 glycylleucine Proteins 0.000 claims 3
108010077112 prolyl-proline Proteins 0.000 claims 3
108010053725 prolylvaline Proteins 0.000 claims 3
AHPWQERCDZTTNB-FXQIFTODSA-N Arg-Cys-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N AHPWQERCDZTTNB-FXQIFTODSA-N 0.000 claims 2
ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 claims 2
KYQJHBWHRASMKG-ZLUOBGJFSA-N Asn-Ser-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O KYQJHBWHRASMKG-ZLUOBGJFSA-N 0.000 claims 2
CPMKYMGGYUFOHS-FSPLSTOPSA-N Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O CPMKYMGGYUFOHS-FSPLSTOPSA-N 0.000 claims 2
101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 claims 2
QJUDRFBUWAGUSG-SRVKXCTJSA-N Cys-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N QJUDRFBUWAGUSG-SRVKXCTJSA-N 0.000 claims 2
JIZRUFJGHPIYPS-SRVKXCTJSA-N Cys-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O JIZRUFJGHPIYPS-SRVKXCTJSA-N 0.000 claims 2
OJGLIOXAKGFFDW-SRVKXCTJSA-N Glu-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)N OJGLIOXAKGFFDW-SRVKXCTJSA-N 0.000 claims 2
YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 claims 2
NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 claims 2
KFMBRBPXHVMDFN-UWVGGRQHSA-N Gly-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCNC(N)=N KFMBRBPXHVMDFN-UWVGGRQHSA-N 0.000 claims 2
SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 claims 2
HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 claims 2
CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 claims 2
VCYVLFAWCJRXFT-HJPIBITLSA-N Ile-Cys-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N VCYVLFAWCJRXFT-HJPIBITLSA-N 0.000 claims 2
GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 claims 2
POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 claims 2
UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 claims 2
CFVQPNSCQMKDPB-CIUDSAMLSA-N Lys-Cys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N CFVQPNSCQMKDPB-CIUDSAMLSA-N 0.000 claims 2
WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 claims 2
IEVXCWPVBYCJRZ-IXOXFDKPSA-N Lys-Thr-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IEVXCWPVBYCJRZ-IXOXFDKPSA-N 0.000 claims 2
UJDMTKHGWSBHBX-IHRRRGAJSA-N Met-Cys-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 UJDMTKHGWSBHBX-IHRRRGAJSA-N 0.000 claims 2
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims 2
HQCSLJFGZYOXHW-KKUMJFAQSA-N Phe-His-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)O)N HQCSLJFGZYOXHW-KKUMJFAQSA-N 0.000 claims 2
XKHCJJPNXFBADI-DCAQKATOSA-N Pro-Asp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O XKHCJJPNXFBADI-DCAQKATOSA-N 0.000 claims 2
LXVLKXPFIDDHJG-CIUDSAMLSA-N Pro-Glu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O LXVLKXPFIDDHJG-CIUDSAMLSA-N 0.000 claims 2
DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 claims 2
HFNPOYOKIPGAEI-SRVKXCTJSA-N Pro-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 HFNPOYOKIPGAEI-SRVKXCTJSA-N 0.000 claims 2
UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 claims 2
UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 claims 2
KPMIQCXJDVKWKO-IFFSRLJSSA-N Thr-Val-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KPMIQCXJDVKWKO-IFFSRLJSSA-N 0.000 claims 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
PMDWYLVWHRTJIW-STQMWFEESA-N Tyr-Gly-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PMDWYLVWHRTJIW-STQMWFEESA-N 0.000 claims 2
OHNXAUCZVWGTLL-KKUMJFAQSA-N Tyr-His-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)O)N)O OHNXAUCZVWGTLL-KKUMJFAQSA-N 0.000 claims 2
230000001772 anti-angiogenic effect Effects 0.000 claims 2
108010069495 cysteinyltyrosine Proteins 0.000 claims 2
108010092114 histidylphenylalanine Proteins 0.000 claims 2
108010064235 lysylglycine Proteins 0.000 claims 2
108010051242 phenylalanylserine Proteins 0.000 claims 2
206010000830 Acute leukaemia Diseases 0.000 claims 1
YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 claims 1
INOIAEUXVVNJKA-XGEHTFHBSA-N Arg-Thr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O INOIAEUXVVNJKA-XGEHTFHBSA-N 0.000 claims 1
BKDDABUWNKGZCK-XHNCKOQMSA-N Asn-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O BKDDABUWNKGZCK-XHNCKOQMSA-N 0.000 claims 1
102100021277 Beta-secretase 2 Human genes 0.000 claims 1
101710150190 Beta-secretase 2 Proteins 0.000 claims 1
101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 claims 1
101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 claims 1
XZFYRXDAULDNFX-UWVGGRQHSA-N Cys-Phe Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UWVGGRQHSA-N 0.000 claims 1
MFMDKTLJCUBQIC-MXAVVETBSA-N Cys-Phe-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MFMDKTLJCUBQIC-MXAVVETBSA-N 0.000 claims 1
101100338242 Drosophila virilis His1.1 gene Proteins 0.000 claims 1
LPHGXOWFAXFCPX-KKUMJFAQSA-N Glu-Pro-Phe Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O LPHGXOWFAXFCPX-KKUMJFAQSA-N 0.000 claims 1
JPUNZXVHHRZMNL-XIRDDKMYSA-N Glu-Pro-Trp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JPUNZXVHHRZMNL-XIRDDKMYSA-N 0.000 claims 1
QCMVGXDELYMZET-GLLZPBPUSA-N Glu-Thr-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QCMVGXDELYMZET-GLLZPBPUSA-N 0.000 claims 1
UMZHHILWZBFPGL-LOKLDPHHSA-N Glu-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O UMZHHILWZBFPGL-LOKLDPHHSA-N 0.000 claims 1
LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 claims 1
NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 claims 1
FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 claims 1
WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 claims 1
DRCKHKZYDLJYFQ-YWIQKCBGSA-N Ile-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRCKHKZYDLJYFQ-YWIQKCBGSA-N 0.000 claims 1
GNLJXWBNLAIPEP-MELADBBJSA-N Lys-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCCN)N)C(=O)O GNLJXWBNLAIPEP-MELADBBJSA-N 0.000 claims 1
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
ZJWIXBZTAAJERF-IHRRRGAJSA-N Lys-Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZJWIXBZTAAJERF-IHRRRGAJSA-N 0.000 claims 1
AHFOKDZWPPGJAZ-SRVKXCTJSA-N Lys-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N AHFOKDZWPPGJAZ-SRVKXCTJSA-N 0.000 claims 1
JPCHYAUKOUGOIB-HJGDQZAQSA-N Met-Glu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPCHYAUKOUGOIB-HJGDQZAQSA-N 0.000 claims 1
101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 claims 1
101100260702 Mus musculus Tinagl1 gene Proteins 0.000 claims 1
101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 claims 1
BYAIIACBWBOJCU-URLPEUOOSA-N Phe-Ile-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BYAIIACBWBOJCU-URLPEUOOSA-N 0.000 claims 1
BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 claims 1
MRYUJHGPZQNOAD-IHRRRGAJSA-N Pro-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 MRYUJHGPZQNOAD-IHRRRGAJSA-N 0.000 claims 1
RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 claims 1
XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 claims 1
SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 claims 1
AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 claims 1
DGDCSVGVWWAJRS-AVGNSLFASA-N Pro-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 DGDCSVGVWWAJRS-AVGNSLFASA-N 0.000 claims 1
208000017442 Retinal disease Diseases 0.000 claims 1
206010038923 Retinopathy Diseases 0.000 claims 1
OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 claims 1
ZHYMUFQVKGJNRM-ZLUOBGJFSA-N Ser-Cys-Asn Chemical compound OC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(N)=O ZHYMUFQVKGJNRM-ZLUOBGJFSA-N 0.000 claims 1
FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 claims 1
241000191940 Staphylococcus Species 0.000 claims 1
TWLMXDWFVNEFFK-FJXKBIBVSA-N Thr-Arg-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O TWLMXDWFVNEFFK-FJXKBIBVSA-N 0.000 claims 1
WFUAUEQXPVNAEF-ZJDVBMNYSA-N Thr-Arg-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CCCN=C(N)N WFUAUEQXPVNAEF-ZJDVBMNYSA-N 0.000 claims 1
XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 claims 1
CUTPSEKWUPZFLV-WISUUJSJSA-N Thr-Cys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(O)=O CUTPSEKWUPZFLV-WISUUJSJSA-N 0.000 claims 1
ODSAPYVQSLDRSR-LKXGYXEUSA-N Thr-Cys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O ODSAPYVQSLDRSR-LKXGYXEUSA-N 0.000 claims 1
BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 claims 1
MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 claims 1
KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 claims 1
GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 claims 1
BRPKEERLGYNCNC-NHCYSSNCSA-N Val-Glu-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N BRPKEERLGYNCNC-NHCYSSNCSA-N 0.000 claims 1
150000001413 amino acids Chemical group 0.000 claims 1
101150088826 arg1 gene Proteins 0.000 claims 1
108010013835 arginine glutamate Proteins 0.000 claims 1
108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 claims 1
108010060035 arginylproline Proteins 0.000 claims 1
208000024207 chronic leukemia Diseases 0.000 claims 1
108010004073 cysteinylcysteine Proteins 0.000 claims 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 1
108010017391 lysylvaline Proteins 0.000 claims 1
230000001613 neoplastic effect Effects 0.000 claims 1
210000000633 nuclear envelope Anatomy 0.000 claims 1
108010029020 prolylglycine Proteins 0.000 claims 1
108010090894 prolylleucine Proteins 0.000 claims 1
238000000034 method Methods 0.000 abstract description 17
230000001965 increasing effect Effects 0.000 abstract description 11
208000030507 AIDS Diseases 0.000 abstract description 10
230000008685 targeting Effects 0.000 abstract description 9
230000003213 activating effect Effects 0.000 abstract description 6
230000006870 function Effects 0.000 abstract description 6
238000009826 distribution Methods 0.000 abstract description 5
230000001681 protective effect Effects 0.000 abstract description 2
210000002889 endothelial cell Anatomy 0.000 abstract 2
238000003745 diagnosis Methods 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 50
239000000872 buffer Substances 0.000 description 42
239000002609 medium Substances 0.000 description 36
230000000694 effects Effects 0.000 description 26
210000001616 monocyte Anatomy 0.000 description 22
238000011534 incubation Methods 0.000 description 19
102000005962 receptors Human genes 0.000 description 19
108020003175 receptors Proteins 0.000 description 19
108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
102100040247 Tumor necrosis factor Human genes 0.000 description 17
108010031318 Vitronectin Proteins 0.000 description 15
102100035140 Vitronectin Human genes 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
102100037362 Fibronectin Human genes 0.000 description 14
108010067306 Fibronectins Proteins 0.000 description 14
230000004913 activation Effects 0.000 description 13
108010065805 Interleukin-12 Proteins 0.000 description 12
102000013462 Interleukin-12 Human genes 0.000 description 12
241000699670 Mus sp. Species 0.000 description 12
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
238000010186 staining Methods 0.000 description 11
102000001327 Chemokine CCL5 Human genes 0.000 description 10
108010055166 Chemokine CCL5 Proteins 0.000 description 10
102000006354 HLA-DR Antigens Human genes 0.000 description 10
108010058597 HLA-DR Antigens Proteins 0.000 description 10
231100000673 dose–response relationship Toxicity 0.000 description 10
102000001902 CC Chemokines Human genes 0.000 description 9
108010040471 CC Chemokines Proteins 0.000 description 9
101150013553 CD40 gene Proteins 0.000 description 9
102100035793 CD83 antigen Human genes 0.000 description 9
101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 9
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 9
210000004980 monocyte derived macrophage Anatomy 0.000 description 9
230000003647 oxidation Effects 0.000 description 9
238000007254 oxidation reaction Methods 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
230000036962 time dependent Effects 0.000 description 9
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 8
108090000054 Syndecan-2 Proteins 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000003993 interaction Effects 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
230000008569 process Effects 0.000 description 8
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
238000011533 pre-incubation Methods 0.000 description 7
241000282693 Cercopithecidae Species 0.000 description 6
125000003275 alpha amino acid group Chemical group 0.000 description 6
230000011748 cell maturation Effects 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
230000006698 induction Effects 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
238000011081 inoculation Methods 0.000 description 6
101710177291 Gag polyprotein Proteins 0.000 description 5
101710125418 Major capsid protein Proteins 0.000 description 5
101100256737 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hlm-1 gene Proteins 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
235000018417 cysteine Nutrition 0.000 description 5
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
230000002779 inactivation Effects 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
238000010212 intracellular staining Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000000242 pagocytic effect Effects 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 4
108010047620 Phytohemagglutinins Proteins 0.000 description 4
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
230000005867 T cell response Effects 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
108010051618 macrophage stimulatory lipopeptide 2 Proteins 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000001885 phytohemagglutinin Effects 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
239000013641 positive control Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108090000978 Interleukin-4 Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003636 conditioned culture medium Substances 0.000 description 3
238000012258 culturing Methods 0.000 description 3
230000006735 deficit Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000000799 fluorescence microscopy Methods 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000012010 growth Effects 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
230000009545 invasion Effects 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
230000003114 pinocytic effect Effects 0.000 description 3
230000037452 priming Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 3
DMWMUMWKGKGSNW-OPMCLZTFSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-[(2R)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](CSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O)OC(=O)CCCCCCCCCCCCCCC DMWMUMWKGKGSNW-OPMCLZTFSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
101100152433 Caenorhabditis elegans tat-1 gene Proteins 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
241001505345 Human T-cell lymphotropic virus type 2b Species 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
241000282560 Macaca mulatta Species 0.000 description 2
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
102000016611 Proteoglycans Human genes 0.000 description 2
108010067787 Proteoglycans Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
241000713311 Simian immunodeficiency virus Species 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
238000004163 cytometry Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
239000003814 drug Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000004807 localization Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
229940023867 prime-boost vaccine Drugs 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
239000012646 vaccine adjuvant Substances 0.000 description 2
229940124931 vaccine adjuvant Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
IXQPRUQVJIJUEB-UHFFFAOYSA-N 7-(diethylamino)-n-[2-(2,5-dioxopyrrol-1-yl)ethyl]-2-oxochromene-3-carboxamide Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C=C1C(=O)NCCN1C(=O)C=CC1=O IXQPRUQVJIJUEB-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
101150096672 CEL1 gene Proteins 0.000 description 1
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
101100480622 Caenorhabditis elegans tat-5 gene Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
102100032999 Integrin beta-3 Human genes 0.000 description 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
241000282553 Macaca Species 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
241001602730 Monza Species 0.000 description 1
241000581002 Murex Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100226116 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) esa-1 gene Proteins 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
101100391171 Schizosaccharomyces pombe (strain 972 / ATCC 24843) for3 gene Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
230000033540 T cell apoptotic process Effects 0.000 description 1
230000029662 T-helper 1 type immune response Effects 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000009460 calcium influx Effects 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000002701 cell growth assay Methods 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229960000900 human factor viii Drugs 0.000 description 1
230000037417 hyperactivation Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
230000019734 interleukin-12 production Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
241001515942 marmosets Species 0.000 description 1
201000006512 mast cell neoplasm Diseases 0.000 description 1
208000006971 mastocytoma Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000011325 microbead Substances 0.000 description 1
230000003641 microbiacidal effect Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
108010032806 molgramostim Proteins 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000008884 pinocytosis Effects 0.000 description 1
108010089520 pol Gene Products Proteins 0.000 description 1
230000000861 pro-apoptotic effect Effects 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000018883 protein targeting Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
206010055031 vascular neoplasm Diseases 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)

OA1200400015A 2001-07-26 2002-07-26 Use of biologically active HIV-1 TAT, fragments orderivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccinati on and/or to treat other diseases. OA12701A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01118114A EP1279404A1 (en)	2001-07-26	2001-07-26	Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases

Publications (1)

Publication Number	Publication Date
OA12701A true OA12701A (en)	2006-06-23

Family

ID=8178141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200400015A OA12701A (en)	2001-07-26	2002-07-26	Use of biologically active HIV-1 TAT, fragments orderivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccinati on and/or to treat other diseases.

Country Status (19)

Country	Link
US (1)	US7811573B2 (pl)
EP (2)	EP1279404A1 (pl)
JP (1)	JP5134183B2 (pl)
CN (1)	CN1318091C (pl)
AP (1)	AP2004002986A0 (pl)
AT (1)	ATE510558T1 (pl)
AU (1)	AU2002331350B2 (pl)
BR (1)	BR0211474A (pl)
CA (1)	CA2455227C (pl)
DK (1)	DK1425035T3 (pl)
EA (1)	EA006850B1 (pl)
ES (1)	ES2367255T3 (pl)
HU (1)	HUP0400660A2 (pl)
IL (1)	IL160015A0 (pl)
MX (1)	MXPA04000287A (pl)
NZ (1)	NZ531364A (pl)
OA (1)	OA12701A (pl)
PL (1)	PL368243A1 (pl)
WO (1)	WO2003009867A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0323840D0 (en) *	2003-10-10	2003-11-12	Ist Superiore Sanita	Vaccines
GB0405480D0 (en)	2004-03-11	2004-04-21	Istituto Superiore Di Sanito	Novel tat complexes,and vaccines comprising them
US20050208482A1 (en)	2004-03-16	2005-09-22	Cohen David I	Tat-based immunomodulatory compositions and methods for their discovery and use
WO2007001448A2 (en)	2004-11-04	2007-01-04	Massachusetts Institute Of Technology	Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
CN100429228C (zh) *	2005-06-17	2008-10-29	中国人民解放军第三军医大学第三附属医院	重组人a20蛋白及其用途
WO2007070682A2 (en)	2005-12-15	2007-06-21	Massachusetts Institute Of Technology	System for screening particles
WO2008105773A2 (en)	2006-03-31	2008-09-04	Massachusetts Institute Of Technology	System for targeted delivery of therapeutic agents
WO2007133807A2 (en)	2006-05-15	2007-11-22	Massachusetts Institute Of Technology	Polymers for functional particles
US9381477B2 (en)	2006-06-23	2016-07-05	Massachusetts Institute Of Technology	Microfluidic synthesis of organic nanoparticles
AU2007284656A1 (en) *	2006-08-14	2008-02-21	Thymon, L.L.C.	Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
EP2134830A2 (en)	2007-02-09	2009-12-23	Massachusetts Institute of Technology	Oscillating cell culture bioreactor
JP2010523595A (ja)	2007-04-04	2010-07-15	マサチューセッツインスティテュートオブテクノロジー	ポリ（アミノ酸）ターゲッティング部分
EP2217269B1 (en)	2007-10-12	2017-04-12	Massachusetts Institute of Technology	Vaccine nanotechnology
GB0802224D0 (en) *	2008-02-06	2008-03-12	Inst Superiore Di Sanito	Process for the production of vaccine components
AU2009212166A1 (en)	2008-02-07	2009-08-13	University Of Washington	Circumferential aerosol device
EP2106803A1 (en) *	2008-04-04	2009-10-07	Fondazione Centro San Raffaele del Monte Tabor	Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
US9439922B2 (en)	2008-05-14	2016-09-13	Jawaharlal Nehru Centre For Advanced Scientific Research	Tat DNA sequences, gene constructs, vaccine and processes thereof
US8343497B2 (en)	2008-10-12	2013-01-01	The Brigham And Women's Hospital, Inc.	Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en)	2008-10-12	2013-11-26	The Brigham And Women's Hospital, Inc.	Nicotine immunonanotherapeutics
US8277812B2 (en)	2008-10-12	2012-10-02	Massachusetts Institute Of Technology	Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en)	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
NZ595060A (en)	2009-03-23	2013-05-31	Pin Pharma Inc	Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
CN102782136A (zh) *	2010-02-18	2012-11-14	爱默蕾大学	表达hiv抗原和gm-csf的载体和用于产生免疫应答的相关方法
US20110287045A1 (en) *	2010-05-20	2011-11-24	Zongdong Li	Enhanced immune response against infections
RU2728583C2 (ru)	2011-03-03	2020-07-30	Импел Ньюрофарма Инк.	Устройство для назальной доставки лекарственных средств
RU2741249C2 (ru)	2011-05-09	2021-01-22	Импел Ньюрофарма Инк.	Наконечники для назальной доставки лекарственных средств
EP2895499B1 (en) *	2012-09-13	2019-04-10	Université de Genève	Cell penetrating peptides
CN103880961A (zh) *	2012-12-19	2014-06-25	邱书奇	一种诱导免疫耐受融合肽构建
WO2014179228A1 (en)	2013-04-28	2014-11-06	Impel Neuropharma Inc.	Medical unit dose container
AU2014329393B2 (en)	2013-10-04	2020-04-30	Pin Pharma, Inc.	Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
ES2804750T3 (es)	2014-04-24	2021-02-09	Janssen Sciences Ireland Unlimited Co	Uso de una proteína accesoria derivada del VIH para la reactivación del VIH latente
IL257845B (en)	2015-09-10	2022-07-01	Impel Neuropharma Inc	In-line nasal delivery device
EP3402802B1 (en)	2016-01-08	2023-04-12	Geovax, Inc.	Compositions and methods for generating an immune response to a tumor associated antigen
CN105535937B (zh) *	2016-03-11	2018-03-13	刘红	一种用于治疗类风湿性关节炎的皮下注射用原位凝胶
ES2964694T3 (es) *	2016-09-15	2024-04-09	Elicera Therapeutics Ab	Inmunoterapia de células T
US11311612B2 (en)	2017-09-19	2022-04-26	Geovax, Inc.	Compositions and methods for generating an immune response to treat or prevent malaria
KR102131898B1 (ko) *	2017-10-31	2020-07-08	주식회사 노벨티노빌리티	Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
JP7191099B2 (ja)	2017-11-21	2022-12-16	インペルファーマシューティカルズインコーポレイテッド	浸漬管を備えた鼻腔内装置
US11395887B2 (en)	2017-11-21	2022-07-26	Impel Pharmaceuticals Inc.	Intranasal device with inlet interface
EP3735223A4 (en)	2018-01-05	2021-10-13	Impel Neuropharma Inc.	INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
AU2019205318B2 (en)	2018-01-05	2022-02-03	Impel Pharmaceuticals Inc.	Intranasal delivery of dihydroergotamine by precision olfactory device
EP3823607A4 (en)	2018-07-19	2022-04-06	Impel NeuroPharma Inc.	ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE
KR20210109007A (ko)	2019-01-03	2021-09-03	임펠 뉴로파마 인코포레이티드	비강 약물 전달 장치
EP3907504A4 (en) *	2019-01-04	2022-11-30	Kyoto University	TEST PROCEDURE FOR ULCERATIVE COLITIS AND PRIMARY SCLEROTIC CHOLANGITIS
BR112021023049A8 (pt)	2019-05-17	2022-10-18	Impel Neuropharma Inc	Dispositivo de dispensação nasal de uso único
TW202112394A (zh)	2019-06-06	2021-04-01	日商電化股份有限公司	以肽核酸為基礎之佐劑
JP7640976B2 (ja) *	2019-12-31	2025-03-06	シァメン・ユニヴァーシティ	分子の細胞内送達用の多量体化送達システム
CN111450082A (zh) *	2020-04-26	2020-07-28	天津大学	一种系统性红斑狼疮治疗纳米颗粒的合成方法
CN115869416A (zh) *	2021-09-28	2023-03-31	上海交通大学医学院附属第九人民医院	用于眼部靶向递药的细胞膜、药物载体、组合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9720585D0 (en) *	1997-09-26	1997-11-26	Smithkline Beecham Biolog	Vaccine
IT1297090B1 (it) *	1997-12-01	1999-08-03	Barbara Ensoli	Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
FI105105B (fi) *	1998-02-27	2000-06-15	Finnish Immunotechnology Ltd O	Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
AU4082300A (en) *	1999-06-21	2001-01-09	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Hiv tat peptides and multiple peptide conjugate system
ES2250151T3 (es)	1999-06-29	2006-04-16	Glaxosmithkline Biologicals S.A.	Uso de cpg como adyuvante de vacuna contra vih.
DE60044303D1 (de)	1999-08-12	2010-06-10	Inist Inc	Nicht-immunsuppresives hiv tat-protein
US6485977B1 (en) *	1999-09-13	2002-11-26	Cornell Research Foundation, Inc.	Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems
PL211762B1 (pl)	2000-01-31	2012-06-29	Smithkline Beecham Biolog	Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki
WO2001054717A1 (en)	2000-01-31	2001-08-02	Vic Jira	Vaccine composition, process and methods
US6544780B1 (en)	2000-06-02	2003-04-08	Genphar, Inc.	Adenovirus vector with multiple expression cassettes
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung

2001
- 2001-07-26 EP EP01118114A patent/EP1279404A1/en not_active Withdrawn
2002
- 2002-07-26 NZ NZ531364A patent/NZ531364A/en not_active IP Right Cessation
- 2002-07-26 CA CA2455227A patent/CA2455227C/en not_active Expired - Fee Related
- 2002-07-26 EP EP02767265A patent/EP1425035B1/en not_active Expired - Lifetime
- 2002-07-26 CN CNB028146581A patent/CN1318091C/zh not_active Expired - Fee Related
- 2002-07-26 WO PCT/EP2002/008377 patent/WO2003009867A1/en not_active Ceased
- 2002-07-26 AP APAP/P/2004/002986A patent/AP2004002986A0/en unknown
- 2002-07-26 PL PL02368243A patent/PL368243A1/pl unknown
- 2002-07-26 US US10/485,180 patent/US7811573B2/en not_active Expired - Fee Related
- 2002-07-26 OA OA1200400015A patent/OA12701A/en unknown
- 2002-07-26 AU AU2002331350A patent/AU2002331350B2/en not_active Ceased
- 2002-07-26 IL IL16001502A patent/IL160015A0/xx not_active IP Right Cessation
- 2002-07-26 DK DK02767265.8T patent/DK1425035T3/da active
- 2002-07-26 EA EA200400227A patent/EA006850B1/ru not_active IP Right Cessation
- 2002-07-26 AT AT02767265T patent/ATE510558T1/de not_active IP Right Cessation
- 2002-07-26 MX MXPA04000287A patent/MXPA04000287A/es not_active Application Discontinuation
- 2002-07-26 ES ES02767265T patent/ES2367255T3/es not_active Expired - Lifetime
- 2002-07-26 HU HU0400660A patent/HUP0400660A2/hu unknown
- 2002-07-26 BR BR0211474-7A patent/BR0211474A/pt not_active IP Right Cessation
- 2002-07-26 JP JP2003515259A patent/JP5134183B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP5134183B2 (ja)	2013-01-30
MXPA04000287A (es)	2005-03-07
US7811573B2 (en)	2010-10-12
ATE510558T1 (de)	2011-06-15
NZ531364A (en)	2005-12-23
PL368243A1 (pl)	2005-03-21
IL160015A0 (en)	2004-06-20
HUP0400660A2 (hu)	2005-01-28
EA006850B1 (ru)	2006-04-28
CN1533284A (zh)	2004-09-29
CN1318091C (zh)	2007-05-30
CA2455227A1 (en)	2003-02-06
EP1425035A1 (en)	2004-06-09
BR0211474A (pt)	2004-07-13
US20050036985A1 (en)	2005-02-17
ES2367255T3 (es)	2011-10-31
AU2002331350B2 (en)	2008-06-12
DK1425035T3 (da)	2011-08-29
WO2003009867A1 (en)	2003-02-06
AP2004002986A0 (en)	2004-03-31
CA2455227C (en)	2012-01-24
EP1279404A1 (en)	2003-01-29
EP1425035B1 (en)	2011-05-25
JP2005505520A (ja)	2005-02-24
EA200400227A1 (ru)	2004-06-24

Publication	Publication Date	Title
EP1425035B1 (en)	2011-05-25	Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
AU2002331350A1 (en)	2003-05-29	Use of biologically active HIV-1 Tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
Fanales-Belasio et al.	2002	Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses
US7744896B1 (en)	2010-06-29	HIV-1 Tat compositions
US6093405A (en)	2000-07-25	Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines
US10688165B2 (en)	2020-06-23	Medicament for use in a method of inducing or extending a cellular cytotoxic immune response
JP2008539751A (ja)	2008-11-20	新規組成物およびその使用
US20040223977A1 (en)	2004-11-11	Fusion peptide HIV vaccines
US20110142911A1 (en)	2011-06-16	HIV epitopes and pharmaceutical composition containing same
NZ243929A (en)	1994-12-22	Compositions of e.coli outermembrane proteins
US20040009194A1 (en)	2004-01-15	Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
Fairman et al.	2009	Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study
Asakura et al.	2000	Th1-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production
Ansari et al.	2004	Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS
MXPA00005325A (en)	2001-12-13	Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination
Boyer et al.	2003	Engineering DNA vaccination as an approach to HIV immune therapy
Toscano et al.	2010	Dendritic cells transduced with lentiviral vectors expressing vasoactive intestinal peptide (Vip) differentiate into vip-secreting tolerogenic-like DC
Tat et al.	1999	DNA Immunization with HIV-1